1.Correspondence to editorial 2 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial”
Sun Young YIM ; Sung Hwan LEE ; Ji Hoon KIM ; Sunyoung S LEE ; Ahmed O KASEB ; Ju-Seog LEE
Clinical and Molecular Hepatology 2025;31(1):e84-e86
2.Correspondence to editorial 2 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial”
Sun Young YIM ; Sung Hwan LEE ; Ji Hoon KIM ; Sunyoung S LEE ; Ahmed O KASEB ; Ju-Seog LEE
Clinical and Molecular Hepatology 2025;31(1):e84-e86
3.Correspondence to editorial 2 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial”
Sun Young YIM ; Sung Hwan LEE ; Ji Hoon KIM ; Sunyoung S LEE ; Ahmed O KASEB ; Ju-Seog LEE
Clinical and Molecular Hepatology 2025;31(1):e84-e86
4.Full mouth rehabilitation with vertical dimension increase in patient with excessive worn dentition due to parafunctional mandibular movements: a case report
JiHoon PARK ; Seong-A KIM ; SunYoung YIM ; JooHyuk BANG ; HeeWon JANG ; YongSang LEE ; KeunWoo LEE
The Journal of Korean Academy of Prosthodontics 2024;62(2):113-122
beyond physiological levels can lead to vertical dimension loss, occlusal imbalance, temporomandibular joint disorders, and periodontal disease. In such cases, prosthodontic restoration becomes necessary emphasizing the importance of appropriate vertical dimension increase and stable occlusion in central relation (CR).In this case, a 74-year-old patient with clenching and grinding habit had severe teeth wear and after assessing interocclusal distance, wear degree, pronunciation, and facial profile, it was decided to perform full-mouth fixed prosthesis restoration with a 4 mm vertical dimension increase. And the significantly displaced Maximum Intercuspal Position (MICP) caused by parafunctional movements was re-established as a stable mutually protective occlusal relationship at centric relation and after a successful 4 months adaptation to provisional restorations, the final prosthesis was fabricated. During 4months of observation periods, stable occlusion in central relation and mutual protection occlusal relationships were maintained and the patient was satisfied with function and aesthetics, leading to this report.
5.Influence of Vitamin C and Maltose on the Accuracy of Three Models of Glucose Meters.
Jooyoung CHO ; Sunyoung AHN ; Jisook YIM ; Younjung CHEON ; Seok Hoon JEONG ; Sang Guk LEE ; Jeong Ho KIM
Annals of Laboratory Medicine 2016;36(3):271-274
No abstract available.
Ascorbic Acid/*chemistry
;
Blood Chemical Analysis/instrumentation/*methods
;
Blood Glucose/*analysis
;
Maltose/*chemistry
6.Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial”
Sung Hwan LEE ; Sun Young YIM ; Ji Hoon KIM ; Sunyoung S. LEE ; Ahmed O. KASEB ; Ju-Seog LEE
Clinical and Molecular Hepatology 2025;31(1):e81-e83
7.Correspondence to letter to the editor on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
Sung Hwan LEE ; Sun Young YIM ; Ji Hoon KIM ; Sunyoung S LEE ; Ahmed O KASEB ; Peng WEI ; Ju-Seog LEE
Clinical and Molecular Hepatology 2025;31(1):e110-e112
8.Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial”
Sung Hwan LEE ; Sun Young YIM ; Ji Hoon KIM ; Sunyoung S. LEE ; Ahmed O. KASEB ; Ju-Seog LEE
Clinical and Molecular Hepatology 2025;31(1):e81-e83
9.Correspondence to letter to the editor on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
Sung Hwan LEE ; Sun Young YIM ; Ji Hoon KIM ; Sunyoung S LEE ; Ahmed O KASEB ; Peng WEI ; Ju-Seog LEE
Clinical and Molecular Hepatology 2025;31(1):e110-e112
10.Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial”
Sung Hwan LEE ; Sun Young YIM ; Ji Hoon KIM ; Sunyoung S. LEE ; Ahmed O. KASEB ; Ju-Seog LEE
Clinical and Molecular Hepatology 2025;31(1):e81-e83